Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831030 | 0.98 | GABRA1 (0.32) | GABRA1GABRB2CTRC | |
| Bromide SCHEMBL5085462 | 0.95 | GABRA1 (0.31) | GABRA1GABRB2CTRC | |
| Iodide SCHEMBL5085340 | 0.95 | GABRA1 (0.31) | GABRA1GABRB2CTRC | |
| SCHEMBL29619533 | 0.82 | GABRA1 (0.41) | GABRA1GABRB2CTRC | |
| SCHEMBL166573 | 0.82 | GABRA1 (0.41) | GABRA1GABRB2CTRC | |
| Bromide SCHEMBL8559533 | 0.80 | — | — | |
| Ammonia Solution, Strong SCHEMBL27539208 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2CTRC | |
| Ethylene SCHEMBL27502363 | 0.76 | GABRA1 (0.38) | GABRA1GABRB2CTRC | |
| SCHEMBL231467 | 0.76 | GABRA1 (0.46) | GABRA1GABRB2 | |
| SCHEMBL4257318 | 0.74 | GABRA1 (0.44) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320718-B | High-barrier transparent flexible display material and preparation method thereof | 中国科学院长春应用化学研究所 | 2020-04-07 | — | — | CN | claimed |
| US-10815395-B2 | Decorative sheet | AICA KOGYO CO., LTD. (JP) | 2020-10-27 | — | — | US | disclosed |
| CN-107848263-B | Decorative sheet | 爱克工业株式会社 | 2020-10-09 | — | — | CN | disclosed |
| CN-109320718-B | High-barrier transparent flexible display material and preparation method thereof | 中国科学院长春应用化学研究所 | 2020-04-07 | — | — | CN | disclosed |
| US-20180201810-A1 | DECORATIVE SHEET | AICA KOGYO CO., LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-1238704-B1 | Catalyst comprising a cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEM (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-1754693-B9 | Process for the production of esters or lactones | DAICEL CHEM (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-1754693-B1 | Process for the production of esters or lactones | DAICEL CHEM (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20100317869-A1 | IMMOBILIZED CYCLIC IMIDE CATALYST AND PROCESS FOR OXIDATION OF ORGANIC COMPOUNDS WITH THE SAME | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-16 | — | — | US | disclosed |
| US-7759515-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compounds using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-1070678-A1 | PROCESS FOR PRODUCING HYDROGEN PEROXIDE | Daicel Chemical Industries, Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6143924-A | Process for producing organic sulfur acids or salts thereof | DAICEL CHEMICAL INDUSTRIES, LTD (JP) | 2000-11-07 | — | — | US | disclosed |
| US-6140396-A | RESIN COMPOSITION INCLUDING N-OXYLS HAVING A SPECIFIC STRUCTURE AND A SYNTHETIC RESIN, SUCH AS A VINYL ESTER RESIN, AN URETHANE(METH)ACRYLATE RESIN, AN UNSATURATED POLYESTER RESIN, A POLYESTER(METH)ACRYLATE RESIN, AND ACRYLIC SYRUP | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-1036788-A1 | Process for producing sulfonic acids or salts thereof | Daicel Chemical Industries, Ltd. (JP) | 2000-09-20 | — | — | EP | disclosed |
| EP-0990631-A1 | PROCESS FOR COOXIDIZING ORGANIC COMPOUNDS, PROCESS FOR PRODUCING EPOXY COMPOUNDS AND PROCESS FOR PRODUCING ESTERS OR LACTONES | Daicel Chemical Industries, Ltd. (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5698332-A | GLYCIDYL (METH)ACRYLATE; LATENT CATALYST | THE DOW CHEMICAL COMPANY (US) | 1997-12-16 | — | — | US | disclosed |
| US-5698641-A | INCLUDES A CATALYST AND A SURFACTANT OR FLOW CONTROL AGENT | THE DOW CHEMICAL COMPANY (US) | 1997-12-16 | — | — | US | disclosed |
| US-5633330-A | Coating composition of non-cyclic polyanhydride and glycidyl oligomer | THE DOW CHEMICAL COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5633020-A | Coating composition of non-cyclic polyanhydride and co-reactant resin | THE DOW CHEMICAL COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5602274-A | USEFUL AS COATING MATERIAL WITH A POLYEPOXIDE; IMPROVED DURABILITY, APPEARANCE, FINISH, AND OXIDATION RESISTANCE | THE DOW CHEMICAL COMPANY (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317869-A1 | IMMOBILIZED CYCLIC IMIDE CATALYST AND PROCESS FOR OXIDATION OF ORGANIC COMPOUNDS WITH THE SAME | AOC2, NOXO1, NOX1 | GABRA1 2852/4885GABRB2 3770/4885CTRC 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.